Mesalazine 400 mg and 800 mg tablets (Asacol): Supply issue

Supply issue Active

Chiesi, the supplier, is out of stock of the 400 mg mesalazine tablets (Pharmacode: 241113 and 2536544) and running low on 800 mg tablets (Pharmacodes: 2470616 and 2536552).

23 October 2025 | 400 mg shipment arrived

Stock of the registered 400 mg product has arrived. The supplier aims to have it out to wholesalers in the week beginning 27 October 2025 (after Labour Day). It can take another 1 to 2 weeks before stock of the registered product reaches pharmacies around New Zealand Aotearoa.

Affected product

Chiesi, the supplier, had a supply issue affecting 400 mg Asacol tablets. 

Chemical: Mesalazine

  • Presentation: Tab 400 mg 
  • Brand: Asacol
  • Pharmacode: 241113 and 2536544
  • Subsidy: $49.50
  • Measure / Qty: per 100

Schedule listing for mesalazine(external link)

Alternative products

400 mg Octasa brand listed 1 October 2025

This product was available to order from early October 2025.

  • Presentation: Tab 400 mg
  • Brand: Octasa
  • Pharmacode: 2714523 
  • Subsidy: $71.00
  • Measure / Qty: per 90
  • Section 29 and wastage apply

Octasa packaging

Octasa packaging is orange and white with a blue pinstripe. The blister pack has blue writing and the tablets are red-brown in colour..
Not shown to scale

Other products

For people taking multiple 400 mg tablets, there are funded options available. Prescribers may need to check Medsafe datasheets for indications and release profiles:

Asacol | Medsafe datasheet [PDF](external link) (1600 mg available)

Pentasa | Medsafe datasheet [PDF](external link)

NZ Formulary monograph for mesalazine(external link) 

Schedule listing for all funded presentations of mesalazine(external link) 

Affected people will need to speak with their health care team about these treatment options. A new prescription will be needed.

1600 mg presentation listed from 1 July 2025

This medicine is not yet approved by Medsafe. As such it needs to be prescribed and dispensed in line with section 29 of the Medicines Act. 

  • Chemical: Mesalazine
  • Brand: Asacol
  • Pharmacode: 2709325
  • Subsidy: $85.50
  • Measure / Qty: per 60
  • Section 29 and wastage claimable

Prescribing and supplying an unapproved medicine

Section 29 of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – such as, a doctor. 

We know supplying a medicine under section 29 is not ideal. In this case, however, this will allow patients to be able to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Advice for prescribing under section 29 – BPAC website(external link) 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website (external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Stock arrived late October 2025

Stock of the registered 400 mg product has arrived. The supplier aims to have it out to wholesalers in the week beginning 27 October 2025 (after Labour Day). It can take another 1 to 2 weeks before stock of the registered product reaches pharmacies around New Zealand Aotearoa.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.  

Sign up to our email list for regular emails about supply issues and more(external link)